On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.
The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.
Read the brief in JClub →